5100 Xizang Glacier Company Limited announced that wholly owned subsidiary Carry Rich Investment Limited entered into a non-binding Memorandum of Understanding on 27 March 2026 with the team led by Professor Yibin Feng at the School of Chinese Medicine, The University of Hong Kong. The five-year framework (effective 26 March 2026 to 25 March 2031) sets out plans for a series of clinical and mechanistic studies assessing the efficacy of “5100” Xizang Glacier Mineral Water in patients with hyperuricemia.
Key elements of the collaboration:
1. Study design and execution • The Professor Team will create randomized, double-blind, controlled trial protocols covering inclusion criteria, intervention methods, follow-up, endpoints, and statistical analysis, and will handle ethics applications and academic oversight. • Carry Rich will supply the mineral water, provide technical data, support patient recruitment, and manage product logistics and compliance. • All trials will adhere to international clinical research standards such as ICH-GCP to safeguard data integrity and reproducibility.
2. Efficacy and safety evaluation • Primary measures include changes in serum uric acid, target attainment rates, renal function, electrolyte balance, and urinary pH. • The Professor Team will monitor adverse events—such as abdominal distension, diarrhoea, and oedema—and compile systematic safety reports. • Carry Rich will participate in progress discussions and help formulate product application strategies based on findings.
3. Data analysis and publication • The Professor Team will manage data, perform statistical analyses, and draft research reports for potential publication in high-impact academic journals and industry white papers. • Both parties will seek to translate results into clinical guidelines, health-management tools, and commercial applications.
4. Extended research scope • Subject to initial results, multi-centre, large-sample studies may follow to verify generalisability and long-term safety. • Mechanistic exploration will target how mineral components influence uric-acid metabolism and renal excretion, potentially informing personalised drinking regimens.
5. Result transformation • Data may underpin scientific promotions, health claims, and regulatory submissions in Mainland China, Hong Kong, and overseas markets. • Opportunities will be explored in digital health platforms, AI-driven assessment tools, and public health education.
The MOU is expressly non-binding, and future definitive agreements remain subject to further negotiation. Shareholders and potential investors are advised to exercise caution when dealing in the company’s shares.
Comments